HCPCS Code J2350: Injection, ocrelizumab, 1 mg (Ocrevus billing guide)

Key Takeaways

HCPCS Code J2350 describes Injection, ocrelizumab, 1 mg – used to bill Ocrevus (Genentech) infusions for multiple sclerosis under Medicare Part B and commercial plans.

Bill 300 units for the standard 300 mg initiation dose and 600 units for the standard 600 mg maintenance dose – 1 mg equals 1 billable unit.

Prior authorization is required by most major commercial payers; accepted ICD-10 codes include G35.A (RRMS) and G35.B0 (PPMS, unspecified).

Pabau’s claims management software helps infusion practices track prior auth status, document NDC numbers, and submit J-code claims without switching between systems.

HCPCS Code J2350 has the official descriptor: Injection, ocrelizumab, 1 mg. It was added to the HCPCS Level II code set maintained by CMS, effective January 1, 2018. Ocrevus itself received FDA approval on March 28, 2017 and was billed under temporary codes until the permanent J2350 code took effect. The code falls under the classification “Drugs Administered Other than Oral Method” within the J-code category.

Ocrevus (ocrelizumab) is a humanized anti-CD20 monoclonal antibody manufactured by Genentech/Roche. The FDA has approved it for two MS indications: relapsing forms of multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS). Both indications are covered under J2350.

One billable unit of J2350 equals 1 mg of ocrelizumab. This is the most operationally critical fact in the code descriptor. Practices that bill in vials rather than milligrams will systematically under- or over-bill.

Dosage, units of service, and how to calculate J2350 billing units

Ocrevus follows a two-phase dosing protocol. Getting the unit count wrong at either phase is the most common J2350 billing error. Here is how the math works:

• Initiation phase: Two 300 mg doses given two weeks apart. Bill 300 units of J2350 per infusion session. Total for the initiation phase: 600 units across two claims.
• Maintenance phase: One 600 mg dose every six months. Bill 600 units of J2350 per infusion session.

Each 300 mg/10 mL single-dose vial provides exactly 300 mg. The maintenance dose requires two vials. Practices running a buy-and-bill model must account for both vials in the claim, which means the units field should reflect the full administered milligram quantity, not a vial count.

Drug waste modifiers: JW and JZ

CMS has required a drug waste modifier on Medicare claims for single-dose vials starting July 1, 2023. Because Ocrevus is supplied in single-dose vials sized to match the standard doses, waste is unlikely under normal dosing. However, practices must still report one of the following modifiers:

• JZ modifier: Append when there is no discarded drug (the full vial content was administered). This is the standard modifier for most J2350 claims at 300 mg or 600 mg doses.
• JW modifier: Append when a portion of the vial was discarded. Report only the administered units on the J2350 line. Add a second J2350 line with the discarded quantity and the JW modifier to account for waste – this supports reimbursement for the wasted drug.

Failing to append either modifier on Medicare claims results in a claim edit that can trigger a denial or a request for documentation. Build this into your medical billing workflow as a pre-submission checklist item.

ICD-10 diagnosis codes that support HCPCS Code J2350 medical necessity

HCPCS Code J2350 claims must carry an ICD-10 diagnosis code that establishes medical necessity. Payers cross-reference submitted diagnosis codes against their coverage policies for ocrelizumab. The two primary accepted codes are:

• G35.A – Relapsing-remitting multiple sclerosis (RRMS)
• G35.B0 – Primary progressive multiple sclerosis, unspecified (PPMS)

Additional PPMS sub-codes (G35.B1 and G35.B2) may be accepted by some payers depending on their current coverage policies. UnitedHealthcare and Blue Cross Blue Shield policies specifically list G35.A and G35.B0 as the supported diagnosis codes for ocrelizumab. Always verify current payer-specific lists before claim submission, as these can be updated with each policy review cycle.

Using an unsupported ICD-10 code is one of the most frequent reasons J2350 claims are denied. Tracking this at the patient record level so that the correct diagnosis code populates automatically on every infusion claim reduces this risk substantially. Accurate documentation in the clinical note also supports audit defense if a payer later questions medical necessity.

NDC numbers required with HCPCS Code J2350

The National Drug Code (NDC) for Ocrevus 300 mg/10 mL single-dose vials is:

• 10-digit format: 50242-150-01
• 11-digit format: 50242-0150-01

NDC reporting requirements vary by payer. Medicare Part B requires NDC reporting on all drug claims submitted on a CMS-1500 or its electronic equivalent (837P). Commercial payers have their own NDC reporting policies, and some require the 11-digit format exclusively. Verify the format requirement before submitting to each commercial plan.

The NDC must reflect the actual product administered, not a substitute or alternate vial lot number. If your practice uses a different lot, confirm the NDC on the vial before claim submission. Pabau’s prescription management tools can store NDC data at the drug product level so it carries through to documentation automatically.

Administration CPT codes to bill alongside HCPCS Code J2350

Ocrevus is administered as an IV infusion, which means the drug charge (J2350) is billed separately from the infusion administration charge. The standard CPT codes for IV infusion administration are:

Ocrevus infusion times vary by dose and patient tolerance. The initiation dose (300 mg) is typically infused over 2.5 hours minimum; the maintenance dose (600 mg) over 3.5 hours minimum when no reactions occur. This means most infusion sessions will require CPT 96413 plus at least two units of CPT 96415. Keep a precise time log in the clinical documentation, as payers may audit infusion time claims against the billed CPT unit count.

Monitoring for infusion reactions is required during and for at least one hour post-infusion. If the practice bills for extended observation separately, ensure the documentation supports the additional time. Consult your practice management system for templates that capture infusion start and stop times at each visit.

Prior authorization requirements for J2350 ocrelizumab billing

Prior authorization (PA) is required by most major commercial payers for Ocrevus. Medicare Advantage plans also frequently require PA; traditional Medicare Part B generally does not, though local coverage determinations can apply. Always check before scheduling the first infusion.

Commercial payer PA criteria for J2350 typically require documentation of all of the following:

• Confirmed diagnosis of RRMS or PPMS with supporting clinical evidence
• Prior treatment history (some plans require a trial of a first-line MS therapy)
• Prescribing neurologist’s attestation of medical necessity
• Most recent MRI findings or relapse documentation
• Patient height, weight, and EDSS score (expanded disability status scale) in some cases

Medical Mutual’s April 2025 prior authorization policy document explicitly lists HCPCS Code J2350 as requiring prior approval for Ocrevus. Moda Health’s criteria similarly require documentation of clinical diagnosis and a prescribing specialist. PA requirements change frequently, so validate current criteria with each payer before each authorization request, not just at initial approval.

Practices managing multiple MS patients on ocrelizumab benefit from a structured PA tracking workflow. Integrating digital forms for prior authorization documentation into the clinical intake process reduces the back-and-forth between clinical and billing staff. When a PA expires before the next infusion cycle, a lapse in coverage can delay treatment with real clinical consequences for the patient.

Streamline your infusion billing from clinical note to claim

Pabau helps infusion practices document NDC numbers, track prior auth status, and submit J-code claims without switching between systems. See how it works for high-cost biologic billing workflows.

Book a demo

Medicare reimbursement and fee schedule for HCPCS Code J2350

Medicare Part B reimburses most physician-administered drugs at ASP+6%, where ASP is the Average Sales Price reported quarterly by manufacturers to CMS. Because ocrelizumab is a high-cost biologic, the reimbursement amounts for J2350 are substantial and updated each quarter.

Three pricing benchmarks matter for J2350 billing:

• ASP (Average Sales Price): The CMS-published price used to calculate Medicare reimbursement. Updated quarterly. Use the CMS Physician Fee Schedule lookup to find the current ASP-based payment amount for J2350.
• WAC (Wholesale Acquisition Cost): The manufacturer’s list price before discounts. Not used for Medicare reimbursement calculations, but often a starting reference point for commercial payer negotiations.
• AWP (Average Wholesale Price): A historically used benchmark that remains relevant for some commercial contracts. AWP is typically higher than ASP.

The buy-and-bill model for Ocrevus means the practice purchases the drug, administers it, and bills the payer. The spread between acquisition cost and reimbursement is where infusion practices generate margin. Because this spread fluctuates with each quarterly ASP update, practices should review reimbursement rates before each infusion cycle, particularly for Medicare patients.

Specialty pharmacy is an alternative to buy-and-bill for commercial patients. Under this model, the payer contracts directly with a specialty pharmacy to dispense Ocrevus, and the practice bills only for administration (CPT 96413/96415).

The correct model for a given patient depends on their payer contract and the practice’s purchasing agreements. Effective EHR integration with your billing system helps track which patients are on buy-and-bill versus specialty pharmacy so the claim logic is applied correctly.

J2350 vs J2351: Understanding the subcutaneous formulation difference

A newer HCPCS code, J2351, covers the subcutaneous (SC) formulation of ocrelizumab: injection, ocrelizumab, 1 mg, and hyaluronidase-ocsq. This is a distinct drug product from the IV formulation billed under HCPCS Code J2350.

Key differences between the two codes:

Billing J2351 when the patient received the IV formulation (or vice versa) constitutes incorrect coding. Payers increasingly use automated claim edits to flag mismatches between the billed HCPCS code and supporting documentation. Confirm the formulation administered before selecting the code. If your practice is transitioning patients from IV to SC ocrelizumab, update the code used on claims from the transition date forward.

Common HCPCS Code J2350 claim denials and how to resolve them

Denials on J2350 claims fall into a predictable set of categories. Knowing the pattern makes resolution faster and prevention easier.

• Missing or invalid prior authorization number: The claim was submitted without a valid PA reference, or the PA expired. Resolution: obtain a valid PA, resubmit with the correct authorization number in the appropriate claim field.
• Unsupported diagnosis code: The submitted ICD-10 code is not on the payer’s accepted list for ocrelizumab. Resolution: review the payer’s clinical policy, confirm the correct ICD-10 code (G35.A or G35.B0), and resubmit with an appeal if needed.
• Unit count mismatch: Units billed do not match the administered dose per the clinical notes. Resolution: review the infusion record, recalculate units (1 mg = 1 unit), and resubmit with a corrected claim.
• Missing JW/JZ modifier on Medicare claims: CMS requires one of these modifiers on all single-dose vial drug claims since July 1, 2023. Resolution: add the appropriate modifier and resubmit.
• NDC not reported or incorrect NDC format: Payer requires NDC reporting but the field was left blank or used the wrong digit format. Resolution: add the correct NDC (50242-0150-01 in 11-digit format) and resubmit.

Most of these denial types are preventable with a pre-submission review checklist. A structured automated workflow that prompts billing staff to verify PA status, diagnosis codes, and modifier selection before claim submission can eliminate the majority of first-pass denials on J2350 claims. Tracking denial patterns by reason code over time reveals which steps in the process need reinforcement.

Documentation requirements for J2350 audit defense

Medicare and commercial payer audits of high-cost biologic claims are common. When a payer requests records for a J2350 claim, the documentation package should include:

• Neurologist’s order or prescription for ocrelizumab with the specific dose, route, and frequency
• Clinical note documenting the MS diagnosis subtype (RRMS or PPMS) and current disease status
• Infusion record with start time, stop time, drug administered (including lot number and NDC), dose in mg, and any adverse reactions
• Prior authorization approval letter from the payer
• Patient-specific medication administration record (MAR)
• NCCI (National Correct Coding Initiative) edit compliance documentation for any bundled codes billed on the same date

Consistent documentation at every infusion session reduces audit risk substantially. Practices using structured medical forms for infusion visits capture all required data points without relying on free-text notes, which are harder to audit and easier to get wrong. The documentation also serves as the evidentiary basis for any PA renewal requests.

The AAPC HCPCS code lookup is a useful reference for verifying code descriptor language and reviewing any applicable coding guidance that supplements the official descriptor.

For a direct free lookup of current HCPCS J2350 data, PGM Billing’s HCPCS lookup tool mirrors CMS data and can be used to verify code status and description without a subscription.

How practice management software supports J2350 billing workflows

Infusion practices billing HCPCS Code J2350 regularly face a layered administrative process: verify PA, document the infusion, capture the NDC, calculate units, apply modifiers, and submit with the correct diagnosis code. Each step is a potential failure point if handled manually or across disconnected systems.

Pabau’s claims management software is built to support exactly this kind of multi-step clinical billing workflow. From patient management through to claim submission, the platform helps practices maintain consistent documentation, track authorization status, and apply the right codes and modifiers without relying on manual lookup at each step.

For practices managing several MS patients on Ocrevus simultaneously, the ability to schedule infusions, document in real time, and generate billing-ready records from a single system reduces the time between treatment and reimbursement.

Explore how HIPAA-compliant medical office workflows can be built around infusion documentation to protect patient data while meeting payer audit requirements. The combination of structured forms, automated workflows, and integrated billing reduces denial rates for high-cost biologics like ocrelizumab without adding headcount.

Conclusion

HCPCS Code J2350 is one of the more operationally demanding J codes in an infusion practice’s billing portfolio. The unit calculation, modifier requirements, diagnosis code specificity, NDC reporting, and prior authorization documentation all have to align on every claim. One missing element generates a denial that delays payment and, in some cases, disrupts the patient’s treatment schedule.

Building a reliable billing workflow around J2350 means standardizing every step from PA initiation through claim submission. Pabau’s practice management and HIPAA-compliant documentation tools help infusion practices do exactly that. To see how Pabau supports high-cost biologic billing workflows, book a demo with the team.

Continue your research

Billing the infusion alongside the drug? CPT code 96413 breaks down the IV infusion administration code you report with each Ocrevus session.

Protecting your buy-and-bill margins? Healthcare revenue cycle management explains how to safeguard reimbursement on high-cost biologic claims.

Comparing tools to cut J-code denials? The best medical billing software for US practices reviews platforms that automate modifier and NDC checks.

Frequently Asked Questions